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Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-threatening familial disorder character-
ized by adrenergically mediated arrhythmias in a structurally 
normal heart that may lead to sudden death.1 Two genetic 
forms of CPVT have been identified: the autosomal-dominant 
variant caused by mutations in the cardiac ryanodine recep-
tor type 2 (RyR2) gene2 and the autosomal-recessive variant 
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caused by mutations in the cardiac calsequestrin 2 (CASQ2) 
gene.3 Additionally, 4 other genes have been associated with a 
clinical spectrum of manifestations consistent with the diag-
nosis of CPVT or with its phenocopies.4–6
Interestingly, RyR2 and CASQ2 mutations induce diastolic 
Ca2+ release from the sarcoplasmic reticulum (SR), leading to 
the development of delayed afterdepolarizations (DADs) and 
triggered activity (TA), which may precipitate life-threatening 
arrhythmias.7–10 This arrhythmogenic mechanism has been 
confirmed in patients during monophasic action potential 
recordings that documented the presence of adrenergically 
mediated DADs and TA in patients with CPVT.11
CPVT, unless promptly diagnosed and treated, may be 
lethal, as documented by the fact that up to 30% of untreated 
individuals die suddenly before the fourth decade of life.12,13 
Clinical management of CPVT is based on treatment with 
β-blockers, which attenuate the consequences of adrenergic 
stimulation, often combined with the sodium channel blocker 
flecainide,14–16 which may directly inhibit TA. Patients unre-
sponsive to this therapy are candidates for implantation of a 
cardioverter-defibrillator,16 which is a most valuable life-sav-
ing therapy but presents a high rate of complications in the 
pediatric population.17 Because the recurrence of life-threat-
ening arrhythmic episodes on medications is quite common in 
patients with CPVT despite compliance with β-blocker ther-
apy (25% recurrences in our unpublished data and 27% in the 
series by Hayashi et al12), there is a need for new therapeutic 
approaches and for the identification of a cure for this disease.
We have recently initiated a set of studies aimed at the 
development of a curative treatment for the recessive form 
of CPVT. In our first published study,18 we demonstrated the 
feasibility of intraperitoneal CASQ2 gene delivery using an 
adeno-associated viral vector (AAV9) in CASQ2 knockout 
newborn mice. The study proved the ability of this approach 
to preserve physiological levels of calsequestrin 2 (CASQ2) 
and its related proteins, triadin and junctin, in the heart of 
CASQ2 knockout mice, and it showed that overexpressed 
CASQ2 localizes properly in the heart of mice and is able to 
prevent DADs, TA, and the development of life-threatening 
arrhythmias.18
Despite these encouraging results, it is clear that the devel-
opment of a curative strategy for CPVT applicable in the clini-
cal setting should prove that (1) the efficacy and lack of side 
effects of viral gene transfer are documented not only in a 
knockout animal model but, most important, in a knock-in 
model of the human disease, (2) there is evidence for long-
term maintenance of the antiarrhythmic response, and (3) the 
treatment is able to prevent the disease when administered in 
neonates and to revert all the phenotypic manifestations when 
therapy is administered in adults.
Accordingly, in the present study, we investigated whether 
the in vivo delivery of the AAV9-CASQ2 construct to homo-
zygous knock-in CASQ2R33Q/R33Q (R33Q) mice would meet 
those criteria. Our study was therefore targeted to investigate 
the ability of AAV9-CASQ2 to prevent the development of 
CPVT in R33Q mice infected at birth, to verify the efficacy of 
the viral gene transfer to prevent the onset of the disease after 
a medium and long period after a single infection delivered at 
birth, and to assess the ability of AAV9-CASQ2 gene delivery 
to revert the disease when administered to adult R33Q mice 
with an overt CPVT phenotype.
Methods
A more detailed description of methods is provided in the online-only 
Data Supplement.
Viral Construct
In the present study, we used an AAV9 carrying the complete cDNA 
of the murine cardiac CASQ2 cotranscribed, through an internal ribo-
some entry site sequence, with the green fluorescent protein (GFP) 
gene as previously described.18
Generation of R33Q Knock-In Mouse Model
A homozygous R33Q knock-in strain was previously generated in 
our laboratory.10 Animals were bred and raised at the Charles River 
Laboratories (Calco, Italy) and transferred to the animal facility at the 
Maugeri Foundation for phenotypic characterization.
AAV9-CASQ2 Infection Procedure in R33Q Mice
The AAV recombinant virus (AAV9-CASQ2) and the empty virus 
(AAV9-GFP) were produced by the AAV Vector Core of the Telethon 
Institute of Genetics and Medicine (Napoli, Italy) according to a pre-
viously published protocol.18 The viral titer was 2.6×1012 genome cop-
ies per milliliter for AAV9-CASQ2 and 4.3×1012 genome copies per 
milliliter for AAV9-GFP. The infection was performed by intraperi-
toneal injection in pups on postnatal day 3 (100 μL), which recovered 
until euthanasia was performed at 6, 9, or 12 months. Three-month-
old mice were anesthetized with Avertin (0.025 mg/kg), and viral par-
ticles (200 μL) were injected into the tail vein and studied 2 months 
later. ECG recordings in mice of either sex were performed with 
implantable loop recorders (Data Sciences International).
In Vitro Electrophysiology
Ventricular myocytes were enzymatically dissociated through aortic 
retrograde perfusion. Action potentials were recorded by use of the 
Figure 1. Long-term postinfection analysis of the efficiency 
and distribution of the green fluorescent protein (GFP)–tagged 
AAV9-CASQ2 construct delivered to newborn R33Q mice. A, 
Estimation of infection rate (40%–50%, as evidenced by the 
merge) of infected GFP-positive cells compared with total 
cells (phase contrast [PhC]). Scale bar, 100 μm; n=3 mice for 
each age. B, Immunohistochemistry analysis with an anti-GFP 
antibody (dark brown) counterstained with hematoxylin (blue) to 
highlight the tissue distribution of AAV9-CASQ2 infection after 
12 months in R33Q-INF. R33Q was used as the negative control. 
Scale bar, 100 μm; n=3 mice.
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whole-cell patch clamp technique in the current-clamp mode and ana-
lyzed with pCLAMP 9.2 (Molecular Devices).
Reverse-Transcription Polymerase Chain Reaction and 
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted and purified from isolated myocytes, liver, lung, 
skeletal muscle, spleen, kidney, testis, and ovary of AAV9-CASQ2–infected 
R33Q and R33Q mice. Real-time polymerase chain reaction quantification 
of mRNA was processed and analyzed as previously described.18
Immunoblotting
Protein expression analysis was performed with the following antibod-
ies: anti-CASQ2 (ABR), anti-triadin,6 anti-junctin,18 anti-RyR2 (ABR), 
anti–α-actinin (Sigma-Aldrich), and anti-cadherin (Sigma-Aldrich).
Immunoprecipitation
Protein-protein interaction was studied by coimmunoprecipitation 
with anti-triadin antibody.6 AAV9-CASQ2–infected R33Q and R33Q 
hearts were washed with PBS and lysed in the presence of protease 
inhibitors according to the manufacturer’s instructions (Dynabeads 
Coimmunoprecipitation Kit, Invitrogen). An unrelated anti-rabbit 
IgG (Promega) was used as negative control.
Immunohistochemistry
Hearts were collected and processed for paraffin embedding. The 
sections were incubated with hematoxylin and eosin and Masson tri-
chrome staining. Immunohistochemical analysis was performed with 
an anti-GFP antibody (Santa Cruz).
Confocal Microscopy
Indirect immunofluorescent labeling of cardiac myocytes isolated 
from AAV9-CASQ2–infected R33Q mice was performed as previ-
ously described.18
Electron Microscopy
Fixed hearts of either sex were embedded in an epoxy resin, and ultra-
thin sections were cut, stained, and analyzed as previously described.10
Statistics
Data are reported as mean±SEM unless otherwise specified. 
Continuous variables were analyzed by the unpaired t test. Categorical 
variables were analyzed by contingency tables with the Fisher exact 
test. We used generalized linear mixed models with a binomial 
Figure 2. Long-term postinfection analysis of 
protein expression and localization in AAV9-
CASQ2 infected newborn R33Q mice. A, 
Protein expression analysis of CASQ2, junctin 
(JnC), and triadin (TrD) in wild-type (WT), 
R33Q, and AAV9-CASQ2–infected newborn 
R33Q (R33Q-INF) mice 12 months after 
infection. B, Protein quantification of CASQ2, 
JnC, and TrD in hearts derived from WT, 
R33Q, and R33Q-INF mice at 12 months (n=3 
mice for each condition). Data are normalized 
to WT levels±SD (*P<0.05). C,Distribution 
of the overexpressed CASQ2 protein in an 
infected green fluorescent protein (GFP)–
positive myocyte 12 months after AAV9-
CASQ2 delivery. CASQ2 is colocalizing with 
α-actinin along the z lines (magnification, 
white arrowheads). Scale bars, 10 μm.
Figure 3. Ultrastructural analysis of calcium release units (CRUs) 
in 12-month-old wild-type (WT), R33Q, and R33Q mice infected 
with AAV9-CASQ2 at birth. Electron micrographs of junctions 
between transverse tubules (TTs) and junctional sarcoplasmic 
reticulum (jSR; ie, CRUs) from WT (a and b), R33Q (a′ and b′), 
and AAV9-CASQ2–infected newborn R33Q (R33Q-INF; a′′ 
and b′′) hearts 12 months after infection (n=3 mice for each 
condition). TTs are labeled in green; JSR is in yellow. Black 
arrows point to the electron-dense polymer of CASQ2 inside the 
jSR lumen. Scale bar, 0.1 μm.
D
ow
nloaded from
 http://ahajournals.org by on Septem
ber 4, 2019
2676  Circulation  June 24, 2014
structure of the errors and a logit link function to investigate whether 
there is a relationship between the responses (DADs and TA) and 
the explanatory variable (the genetic group: wild type [WT], R33Q, 
R33Q-INF, R33Q-GFP). Accordingly, DADs and TA were scored as 
present (1) or absent (0) in the mice. Cells, mice, and time since infec-
tion were random-effect variables, and genetic group was the explana-
tory variable. Model simplification was also used to obtain minimal 
adequate models.19 We used the likelihood ratio test for model selec-
tion, Wald z test for comparing 2 factor levels, and Dunnett contrasts 
for multiple comparisons. All statistical analyses were carried out with 
R software. Values of P<0.05 were considered statistically significant.
Results
Results are presented for 2 sets of experiments. The data in the 
first sections are related to the protocol designed to test whether 
a single injection of the AAV9-CASQ2 delivered at birth in 
R33Q mice is able to prevent the development of CPVT up to 
1 year of age corresponding to advanced age for mice. The sec-
ond set of data relate to the protocol designed to test whether a 
single injection of the AAV9-CASQ2 construct in adult R33Q 
mice is able to revert phenotypic manifestations of CPVT.
Efficacy and Long-Term Persistence of the Effects 
of a Single Injection of AAV9-CASQ2 at Birth in 
R33Q Mice
We studied 3 groups of mice at different times (6, 9, and 
12 months) after injection to characterize the effect of ther-
apy on (1) efficiency of infection; (2) levels of CASQ2 and 
its associated proteins, triadin and junctin; (3) architecture of 
calcium release units (CRUs); (4) in vitro response of R33Q 
myocytes to isoproterenol; and (5) adrenergically mediated 
arrhythmogenesis in vivo.
Efficiency of AAV9-CASQ2 Infection
We quantified the infection rate by epifluorescent analysis in 
isolated ventricular cardiomyocytes in R33Q mice infected at 
birth with AAV9-CASQ2 (R33Q-INF). We observed an infec-
tion rate between 40% and 50% (Figure 1A). As depicted 
in Figure 1B, the viral distribution, detected by a specific 
anti-GFP immunohistochemistry, revealed a mosaic expres-
sion into cardiac tissues. GFP expression was quantified by 
real-time polymerase chain reaction in different organs. As 
expected for AAV9,20–22 cardiac myocytes were the main tar-
get of the viral infection (Figure IA in the online-only Data 
Supplement). Histological analysis did not reveal structural 
abnormalities or inflammation in infected hearts at 12 months 
(Figure IB in the online-only Data Supplement).
Levels of CASQ2 and Its Associated Proteins,  
Triadin and Junctin
The cardiac mRNA expression analysis by real-time poly-
merase chain reaction of CASQ2 did not evidence significant 
changes in the endogenous transcript in R33Q and R33Q-
INF mice (Figure IIA in the online-only Data Supplement). 
Comparison between endogenous and total transcript in R33Q-
INF mice provided evidence of the increase in CASQ2-mRNA 
caused by the AAV9 infection (Figure IIB in the online-only 
Data Supplement). Furthermore, the protein analysis in R33Q 
and R33Q-INF mice allowed us to point out the increased level 
of AAV-induced CASQ2 (Figure IIC and IID in the online-only 
Data Supplement). The expression of CASQ2 and its ancillary 
partners, junctin and triadin, in CASQ2WT/WT (WT), R33Q, and 
R33Q-INF mice was analyzed 12 months after viral infec-
tion. In agreement with our previous report,10 we documented 
that the homozygous R33Q mice present a major reduction in 
levels of CASQ2, junctin, and triadin as assessed by Western 
blot analysis (−62% in CASQ2, −42% in junctin, and −24% 
in triadin at 12 months; Figure 2A and 2B). In the R33Q-INF 
animals, however, there was a significant recovery of the levels 
of the 3 proteins (Figure 2A and 2B). We assessed the cellular 
distribution of the virally induced CASQ2, showing that it cor-
rectly localized along the z lines (Figure 2C). A comparison of 
CASQ2 expression between R33Q and R33Q-INF myocytes is 
shown in Figure III in the online-only Data Supplement.
Figure 4. In vitro electrophysiological 
analysis after AAV9-CASQ2 infection in 
newborn R33Q mice. A, Action potentials 
elicited at 5 Hz (arrows) after exposure to 
30 nmol/L isoproterenol (ISO) in isolated 
myocytes from wild-type (WT), R33Q, and 
AAV9-CASQ2–infected R33Q (R33Q-INF) 
mice at 12 months. Quantification of the 
incidence of (B) isoproterenol-induced 
delayed afterdepolarizations (DADs; defined 
as phase 4 positive transient depolarizing 
deflections of the membrane potentials) 
and (C) triggered activity (TA; defined as an 
unstimulated action potential developing 
from a DAD) in all groups of WT, R33Q, and 
R33Q-INF myocytes: DADsWT, 5 of 60 cells; 
DADsR33Q, 47 of 61 cells; DADsR33Q-INF, 3 of 54 
cells; TAWT, 3 of 60 cells; TAR33Q, 38 of 61 cells; 
and TAR33Q-INF, 1 of 54 cells. ***P<0.001, R33Q-
INF vs R33Q and WT vs R33Q (n=3 mice for 
each condition).
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Architecture of CRUs
We recently reported the presence of ultrastructural abnormal-
ities in R33Q mice characterized by widening of the cisternae 
of junctional SR (jSR) and fragmentation and heterogeneity 
of couplons.10,18,23 Furthermore, we observed an absence of the 
electron-dense CASQ2 polymer in the jSR cisternae.
Here, we show that infection with AVV9-CASQ2 in neo-
nate R33Q mice prevents the development of abnormal jSR 
and avoids the loss of CASQ2 polymers and the enlargement 
of jSR cisternae (jSR width, 33±8 nm in R33Q, 24±7 nm in 
R33Q-INF; P<0.001; Figure 3). Interestingly, in mice infected 
with an empty AAV9 vector (R33Q-GFP), there was no rescue 
of the abnormal CRUs (jSR width in R33Q-GFP, 36±11 nm; 
Figure IV in the online-only Data Supplement).
Electrophysiological Response of R33Q Myocytes 
to Isoproterenol
Action potentials of paced (5 Hz) ventricular myocytes 
derived from WT, R33Q, and R33Q-INF mice infected at 
birth were recorded by patch-clamp technique to assess the 
arrhythmogenic response to β-adrenergic stimulation (iso-
proterenol 30 nmol/L) at different ages (6, 9, and 12 months). 
The AAV9-CASQ2 delivery achieved a striking reduction 
in isoproterenol-induced DADs and TA, preventing the 
development of the arrhythmogenic phenotype observed in 
myocytes isolated from R33Q mice (P<0.001, R33Q-INF 
versus R33Q; Figure 4).
Adrenergically Mediated Arrhythmogenesis In Vivo
WT, R33Q and R33Q-INF mice were instrumented with an 
implantable ECG recorder to compare the incidence of arrhyth-
mias after adrenergic stimulation (epinephrine 2 mg/kg) at 6, 9, 
and 12 months after virally mediated AAV9-CASQ2 delivery. 
As shown in Figure 5A and 5B, R33Q mice presented a remark-
able incidence of polymorphic and bidirectional ventricular 
tachycardia, whereas R33Q-INF mice showed a highly signifi-
cant suppression of the arrhythmic events (P<0.001, R33Q-INF 
versus R33Q and R33Q-INF versus R33Q-GFP).
Ability of a Single Infection With the AAV9-CASQ2 
Construct to Revert the CPVT Phenotype in Adult 
Symptomatic R33Q Mice
Three-month-old R33Q mice were instrumented with ECG 
telemetry to test for arrhythmia susceptibility after administra-
tion of epinephrine. Mice that developed either polymorphic 
or bidirectional ventricular tachycardia were randomized into 
2 groups based on the response to this initial test: R33Q mice 
receiving no viral gene transfer (n=9) and R33Q mice infected 
Figure 5. In vivo ECG recording after medium- 
and long-term AAV9-CASQ2 infection in 
newborn R33Q mice. A, In vivo epinephrine 
administration elicited bidirectional ventricular 
tachycardia in R33Q and R33Q-GFP, but not 
in WT or AAV9-CASQ2–infected, newborn 
R33Q (R33Q-INF) mice. B, Quantification of the 
incidence of ventricular tachycardia (VT) in WT, 
R33Q, R33Q-INF, and R33Q-GFP mice after 
6, 9, and 12 months (VTWT-6 months, 0 of 9 mice; 
VTWT-9 months, 0 of 9 mice; VTWT-12 months, 0 of 6 mice; 
VTR33Q-6 months, 8 of 9 mice; VTR33Q-9 months, 9 of 10 
mice; VTR33Q-12 months, 8 of 8 mice; VTR33Q-INF-6 months, 
1 of 10 mice; VTR33Q-INF-9 months, 0 of 8 mice; VTR33Q-
INF-12 months, 0 of 8 mice; and VTR33Q-GFP-12 months, 7 of 
8 mice. ***P<0.001, R33Q-INF vs R33Q and 
R33Q-INF vs R33Q-GFP.
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with either AAV9-CASQ2 (n=13) or AAV9-GFP (empty vec-
tor; n=3). Two months after the infection, we re-exposed them 
to ECG challenge and performed molecular, ultrastructural, 
and electrophysiological assays.
Efficiency of AAV9-CASQ2 Infection
The infection rate was calculated by epifluorescent analysis 
of GFP expression in isolated cardiac myocytes (Figure 6A). 
AAV9-CASQ2 virus delivered in adult mice achieved an infec-
tion rate comparable to that of infected newborn mice (≈40%).
Levels of CASQ2, Triadin, and Junctin
Cardiac mRNA expression analysis of CASQ2 from R33Q 
and R33Q-INF mice did not provide evidence of significant 
changes in the endogenous transcript (Figure VA in the online-
only Data Supplement). The comparison between the endoge-
nous and total transcript in R33Q-INF provided evidence of the 
increase in CASQ2-mRNA resulting from the AAV9 infection 
(Figure VB in the online-only Data Supplement). Furthermore, 
protein analysis in R33Q and R33Q-INF mice allowed us to 
point out the increased level of AAV-induced CASQ2 (Figure 
VC and VD in the online-only Data Supplement). Two months 
after infection with AAV9-CASQ2, a normalization of the lev-
els of expression of CASQ2, triadin, and junctin was observed 
(Figure 6B). At the same time, coimmunoprecipitation experi-
ments with a specific anti-triadin antibody (Figure 6C and 6D) 
showed that infected cells preserve and restore the physiologi-
cal protein-protein interactions between triadin and CASQ2 
and between triadin and junctin, respectively.
Architecture of CRUs
We performed electron microscopy on cardiac tissue of R33Q 
and R33Q-INF mice. As shown in Figure 7A, the AAV9-
CASQ2 infection reverted the abnormal morphology of the 
jSR typical of R33Q mice, inducing a significant reduction 
in the width of the jSR in R33Q-INF (from 34±9 nm in R33Q 
to 24±4 nm in R33Q-INF; P<0.001). In R33Q-INF hearts, 
we observed the simultaneous presence of cells with restored 
CRUs (likely the infected cells) and cardiomyocytes with an 
abnormal architecture (possibly noninfected cells; Figure 7B).
Electrophysiological Response of R33Q Myocytes to 
Isoproterenol
Functional analysis was accomplished by in vitro electrophys-
iology on isolated cardiomyocytes derived from the hearts of 
R33Q, R33Q-GFP, and R33Q-INF mice (Figure 8A). The 
action potential profiles elicited at 5 Hz after β-adrenergic 
stimulation (isoproterenol 30 nmol/L) revealed a remarkable 
decrease in the percentage of DADs and TA in R33Q-INF ver-
sus R33Q cells (P<0.007 for both DADs and TA; Figure 8A 
and the Table).
Adrenergically Mediated Arrhythmogenesis In Vivo
In vivo evaluation of arrhythmias susceptibility was per-
formed by ECG recordings in R33Q, R33Q-GFP, and R33Q-
INF mice 2 months after viral gene transfer treatment. An 
epinephrine test revealed a remarkable reduction in the occur-
rence of ventricular tachycardia in R33Q-INF mice compared 
with R33Q mice (P<0.001) and R33Q-GFP mice (P<0.05; 
(Figure 8B and the Table).
In a global evaluation of the consequence of administering 
a single dose of AAV-CASQ2 therapy in adult R33Q mice, we 
observed a complete recovery of all the phenotypic manifesta-
tions of the recessive CPVT that were present before treatment.
Discussion
The recessive form of CPVT, associated with different 
CASQ2 mutations, shares with the autosomal-dominant form 
of CPVT the same final pathway of SR Ca2+ overload, spon-
taneous diastolic SR Ca2+ release, and Ca2+ oscillations after 
adrenergic stimulation that represent a highly arrhythmogenic 
situation.24,25 The complex pathogenesis of CASQ2-related 
CPVT is a remarkable example of how a single gene mutation, 
which determines primarily drastic instability and a reduction 
in the mutant protein, triggers a cascade of events resulting in 
biophysical, proteomic, and ultrastructural abnormalities.9,10,22 
Our group has recently demonstrated that it is possible to cor-
rect the CPVT phenotype in CASQ2 knockout mice by AAV 
transfer of the CASQ2 gene.18 However, to replicate what hap-
pens in the human form of the disease, we tested our gene 
Figure 6. Molecular characterization of AAV9-CASQ2 
infection in adult R33Q mice. A, Evaluation of the 
efficiency of AAV9-CASQ2 infection in adult R33Q 
mice 2 months after injection. The rate of viral infection 
was ≈40% (as shown by the merge) according to the 
number of green-fluorescent protein (GFP)–positive 
cells vs total myocytes (phase contrast [PhC]; n=4 
mice). B, Protein expression analysis in wild-type (WT), 
R33Q, and R33Q AAV9-CASQ2–infected (R33Q-INF) 
mice. Western blots were performed to detect CASQ2, 
triadin (TrD), and junctin (JnC). Cadherin was used as 
the loading control (n=3 mice for each condition). C and 
D, Coimmunoprecipitations (IP) in R33Q and R33Q-
INF hearts with anti-TrD antibody and immunoblotted 
(IB) with anti-CASQ2 (C) and anti-JnC (D) antibody. 
Cadherin was used as the loading control. An infected 
heart incubated with unrelated antibody was used as the 
negative control (Ctrl).
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therapy approach in the homozygous R33Q knock-in mouse 
model, characterized by the expression of an endogenous 
defective CASQ2 protein.10 This model is a bigger challenge 
for the viral gene transfer approach because it is difficult to 
predict whether the overexpressed wild-type CASQ2 would 
polymerize with the mutant protein to rescue the composite 
phenotypic manifestations of the disease.
Data presented in this work prove that a single administra-
tion of the viral construct AAV9-CASQ2 displays long-last-
ing efficiency in mice infected at birth and is able to revert 
the phenotype in adult symptomatic mice. These 2 protocols 
simulate 2 distinct clinical scenarios for the delivery of gene 
therapy to infants genotyped at birth and to symptomatic indi-
viduals diagnosed later in life.
The AAV9-CASQ2 infection rate in cardiac cells resulted in 
≈40% after delivery of the construct in both neonates and adult 
animals. The functional characterizations combining in vivo and 
in vitro electrophysiology demonstrated comparable features in 
AAV infection in newborns and in symptomatic adults, proving 
that the efficacy of the viral delivery of CASQ2 is independent 
of the time of administration of the viral construct. As expected, 
the virus localized preferentially into the heart, as demonstrated 
by real-time GFP expression and immunohistochemical analy-
sis. The systemic administration of AAV9-CASQ2 was able to 
restore the physiological protein levels of CASQ2, triadin, and 
junctin, providing evidence of their high interdependence and 
the appropriate localization in the cardiac myocytes.
In addition, coimmunoprecipitation in infected R33Q 
adult mice suggests that the overexpressed CASQ2 is also 
Figure 7. Ultrastructural analysis of the calcium release units 
(CRUs) in adult R33Q mice infected with AAV9-CASQ2. A, 
Electron micrographs of junctions between transverse tubules 
(TTs) and junctional sarcoplasmic reticulum (jSR; ie, CRUs) 
from R33Q and AAV9-CASQ2–infected adult R33Q (R33Q-INF) 
hearts (n=3 mice for each condition). TTs are labeled in green; 
jSR is in yellow. Black arrows point to the electron-dense chain-
like polymer of CASQ2 inside the SR lumen. Scale bar, 0.1 μm. 
B, Electron micrograph showing 2 adjacent cardiomyocytes 
from R33Q-INF mouse. The cell on the left contains abnormal 
CRUs (a and b). These CRUs present a wide and irregular SR 
lumen typical of a R33Q cell, whereas the other cardiac cell (right) 
contains structurally restored CRUs (c and d) with a narrow lumen 
and chain-like electron CASQ2 polymer. Scale bars, 0.1 and 1 μm.
Figure 8. In vitro and in vivo evaluation of susceptibility to 
arrhythmia in adult R33Q mice after AAV9-CASQ2 infection. 
A, Incidence of isoproterenol (ISO)-induced delayed afterde-
polarizations (DADs) and triggered activity (TA) in infected 
cardiomyocytes (R33Q-INF) vs control cells (R33Q and R33Q-
GFP): DADsR33Q, 15 of 19 cells; DADsR33Q-INF, 3 of 17 cells; 
DADsR33Q-GFP, 9 of 12 cells; TAR33Q, 12 of 19 cells; TAR33Q-INF, 2 
of 17 cells; and TAR33Q-GFP, 7 of 12 cells. **P<0.007, R33Q-INF 
vs R33Q (n=3 mice). B, Quantification of animals presenting 
ventricular tachycardia (VT) episodes in the resting condition 
and after epinephrine administration in adult R33Q (n=9), R33Q-
GFP (n=3), and R33Q-INF (n=13) mice. ***P<0.001, R33Q-INF vs 
R33Q; *P<0.05, R33Q-INF vs R33Q-GFP. GFP indicates green 
fluorescent protein.
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able to retain the physiological protein-protein interaction 
between triadin and CASQ2 and to restore the molecular 
binding, missed in R33Q mice, between triadin and junctin. 
Interestingly, we have shown that our gene therapy strategy 
is able to recover protein levels and to revert the jSR widen-
ing and fragmentation23 seen in CRUs of R33Q.10 It is also 
remarkable that electron microscopy allowed to appreciate the 
correct localization of the overexpressed CASQ2 in the jSR as 
documented by the reappearance of the chain-like polymers of 
CASQ2 in the jSR.26,27
A puzzling question raised by our study is why, even though 
the AAV9-CASQ2 construct does not reach all cardiac cells, 
it induces a remarkable antiarrhythmic efficacy. We believe 
that biophysical properties that regulate the propagation of the 
action potential in the heart may provide an explanation for this 
apparently surprising effect. Accordingly, for a triggered action 
potential to elicit a premature ventricular complex, it has to be 
able to propagate to adjacent cells. Because action potential 
propagation follows the “source-sink” relationship, both active 
and passive properties of the cardiac tissue determine whether 
an action potential is able to travel from cell to cell. It is only 
when adjacent myocytes develop synchronous DADs that the 
summation of the multiple depolarizations allows propagation 
of a triggered action potential to the entire heart. The experi-
mental demonstration of this concept has been provided in a 
most elegant in silico study by Xie et al.28 These authors cal-
culated the number of adjacent cells required for a DAD to 
generate an action potential and showed that an afterdepolar-
ization is suppressed unless a sufficient number of the neigh-
boring myocytes develop an afterdepolarization on the same 
beat. Therefore, to prevent propagation of triggered beats, it is 
not required that all cells are rescued; it is enough that a frac-
tion of them impair propagation of action potentials to prevent 
life-threatening arrhythmias.
The need for novel and more effective therapies for CPVT 
and the efficacy observed in our recessive CPVT animal mod-
els of CASQ2 viral gene delivery open the door to gene therapy 
for CPVT. The recent Calcium Up-Regulation by Percutaneous 
Administration of Gene in Cardiac Disease (CUPID) study 
showed the safety and efficacy of AAV-mediated cardiac deliv-
ery of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a 
(SERCA2a) gene in heart failure patients.29 These results, com-
bined with the first marketing approval by European Medicines 
Agency of an AAV gene therapy for lipoprotein lipase defi-
ciency,30,31 provide a solid rationale for planning the clinical 
testing of AAV gene therapy for other diseases with unmet 
clinical needs such as recessive CPVT.
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CLINICAL PERSPECTIVE
Homozygous mutations in the CASQ2 gene encoding for human calsequestrin-2, a protein that regulates calcium homeosta-
sis, cause the recessive variant of catecholaminergic polymorphic ventricular tachycardia (CPVT). CPVT predisposes the 
hearts of patients to cardiac arrest elicited by stress and emotion. CPVT patients receive lifelong therapy with β-blockers 
to prevent cardiac arrest. Development of “curative” strategies to restore normal gene function is an attractive goal for the 
treatment of CPVT: a highly penetrant, life-threatening disease. In 2008, we developed and characterized a knock-in mouse 
model that recapitulates the human phenotype of recessive CPVT and harbors the R33Q mutation in the CASQ2 gene. Here, 
we explore the therapeutic potential of viral gene transfer of wild-type CASQ2 in R33Q mice using an adeno-associated virus 
serotype 9 (AAV9). In vivo delivery of the AAV9-CASQ2 to R33Q mice prevents the development of the CPVT phenotype 
when therapy is administered to newborn R33Q mice and reverts the manifestations of the disease when administered to 
adult R33Q mice with full-blown signs of the disease. In the R33Q CPVT mice model, our gene therapy strategy shows 
long-term efficacy and selective expression of the transgene in the heart. The present data provide the first demonstration 
that delivery of the wild-type CASQ2 gene is able not only to prevent the onset of disease but also to revert its multifac-
eted manifestations, including abnormal protein expression, altered architecture of junctional sarcoplasmic reticulum, and 
cardiac arrhythmias. These preclinical data provide the rational for envisioning viral gene transfer as a novel therapeutic 
approach in CPVT patients.
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